Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

While immune checkpoint inhibitors targeting the CTLA-4 and PD-1 receptors have significantly improved outcomes of many patients with metastatic melanoma, there remains a group of patients who demonstrate no benefit. In this study, we sought to characterise patients who do not respond to anti-PD-1-b...

Full description

Bibliographic Details
Main Authors: Tuba N. Gide, Inês Pires da Silva, Camelia Quek, Peter M. Ferguson, Marcel Batten, Ping Shang, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P. M. Saw, John F. Thompson, Richard A. Scolyer, Georgina V. Long, James S. Wilmott
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
immunotherapy resistance
tumour-infiltrating lymphocytes
RNA-sequencing
melanoma
anti-PD-1
anti-CTLA-4
Online Access:https://www.mdpi.com/2072-6694/13/13/3186

Internet

https://www.mdpi.com/2072-6694/13/13/3186

Similar Items